Literature DB >> 8398843

Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)

J K Phillips1, G Majumdar, B J Hunt, G F Savidge.   

Abstract

Heparin-induced skin reaction is a recognized complication of subcutaneously administered, unfractionated heparin, and has recently been described in association with the use of two LMWH preparations, Fragmin and Fraxiparin. We describe the case of a 25-year-old woman in whom characteristic skin lesions were induced on separate occasions by unfractionated heparin, Fragmin and a third preparation of LMWH, Clexane. This case demonstrates that substitution of one preparation of heparin for another does not prevent recurrence of skin reaction in susceptible patients. Alternative anticoagulants should be considered in these cases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8398843     DOI: 10.1111/j.1365-2141.1993.tb03080.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Hypersensitivity to nadroparin calcium : case report and review of the literature.

Authors:  Didier G Ebo; Steven E Haine; Margo M Hagendorens; Chris H Bridts; Viviane M Conraads; Ann Vorlat; Chris J Vrints; Luc S De Clerck; Wim J Stevens
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 2.  Low molecular weight heparins: a guide to their optimum use in pregnancy.

Authors:  Pierre Laurent; Guy-Vincent Dussarat; Jacques Bonal; Christophe Jego; Philippe Talard; Christian Bouchiat; Gilles Cellarier
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.

Authors:  R Wütschert; P Piletta; H Bounameaux
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

4.  Generalised cutaneous necrosis: a complication of low-molecular-weight heparin.

Authors:  Girish K Patel; Arthur G Knight
Journal:  Int Wound J       Date:  2005-09       Impact factor: 3.315

Review 5.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 6.  Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.

Authors:  S Noble; D H Peters; K L Goa
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.